Inhibrx Biosciences Inc (INBX) Stock Statistics & Valuation Metrics

Inhibrx Biosciences Inc has a market cap or net worth of $1.28B. The enterprise value is $1.53B.

Market Cap

$1.28B

Enterprise Value

$1.53B

Inhibrx Biosciences Inc has 14,717,660 shares outstanding. The number of shares has decreased by -2.65% in one year.

Shares Outstanding

14,717,660

Owned by Insiders

15.62%

Owned by Institutions

30.29%

Inhibrx Biosciences Inc’s return on equity (ROE) is -17.52 and return on invested capital (ROIC) is -117.41%.

Return on Equity (ROE)

-17.52

Return on Assets (ROA)

-0.96

Return on Invested Capital (ROIC)

-117.41%

Return on Capital Employed (ROCE)

-1.20

Revenue Per Employee

11.82K

Profits Per Employee

-1.27M

Employee Count

110

Asset Turnover

0.01

Inventory Turnover

0.00

The current PE Ratio of Inhibrx Biosciences Inc is -9.04. Inhibrx Biosciences Inc’s PEG ratio is -0.49.

PE Ratio

-9.04

PS Ratio

0.00

PB Ratio

-23.74

Price to FCF

-8.96

Price to Operating Cash Flow

-9.54

PEG Ratio

-0.49

In the last 12 months, Inhibrx Biosciences Inc had revenue of 1.30M and earned -140.06M in profits. Earnings per share was -9.04.

Revenue

1.30M

Gross Profit

-1.18M

Operating Income

-135.03M

Pretax Income

-140.05M

Net Income

-140.06M

EBITDA

-125.37M

Earnings Per Share (EPS)

-9.04

In the last 12 months, operating cash flow was -131.89M and capital expenditures 17,000, giving a free cash flow of -131.87M billion.

Operating Cash Flow

-131.89M

Free Cash Flow

-131.87M

Free Cash Flow per Share

-8.42

Inhibrx Biosciences Inc pays an annual dividend of $0.85, resulting in a dividend yield of ―

Dividend Per Share

$0.85

Dividend Yield

―

Payout Ratio

N/A

Free Cash Flow Yield

-11.16%

Earnings Yield

-10.98%

Beta

1.39

52-Week Price Change

-2.42%

50-Day Moving Average

101.21

200-Day Moving Average

92.46

Relative Strength Index (RSI)

42.73

Average Volume (3m)

312.54K

Inhibrx Biosciences Inc upcoming earnings date is Nov 13, 2026, TBA (Not Confirmed).

Last Earnings Date

Aug 13, 2026

Next Earnings Date

Nov 13, 2026

Ex-Dividend Date

May 30, 2024

Inhibrx Biosciences Inc as a current ratio of 3.93, with Debt / Equity ratio of 1338.82%

Current Ratio

3.93

Quick Ratio

3.93

Debt to Market Cap

0.08

Net Debt to EBITDA

0.14

Interest Coverage Ratio

-11.07

In the past 12 months, Inhibrx Biosciences Inc has paid 2,000 in taxes.

Income Tax

2,000

Effective Tax Rate

-0.00

Inhibrx Biosciences Inc EV to EBITDA ratio is -8.75, with an EV/FCF ratio of -7.99.

EV to Sales

0.00

EV to EBITDA

-8.75

EV to Free Cash Flow

-7.99

EV to Operating Cash Flow

-7.99

Inhibrx Biosciences Inc has $133.34M in cash and marketable securities with $5.34M in debt, giving a net cash position of $128.00M billion.

Cash & Marketable Securities

$133.34M

Total Debt

$5.34M

Net Cash

$128.00M

Net Cash Per Share

$8.70

Tangible Book Value Per Share

-$3.38

Gross margin is 0.00%, with operating margin of 0.00%, and net profit margin of 0.00%.

Gross Margin

0.00%

Operating Margin

0.00%

Pretax Margin

0.00%

Net Profit Margin

0.00%

EBITDA Margin

0.00%

EBIT Margin

0.00%

The average price target for Inhibrx Biosciences Inc is $266.67, which is 11.43% higher than the current price. The consensus rating is Strong Buy

Price Target

$266.67

Price Target Upside

232.17% Upside

Analyst Consensus

Strong Buy

Analyst Count

3

Revenue Growth Forecast

-100.00%

EPS Growth Forecast

19.23%

Smart Score

7

AI Score

45